Biotechnology

Innate Pharma announced its total outstanding shares and voting rights as of July 3, 2025. The company reported 92,183,523 ordinary shares and 6,434, plus 7,581 preferred shares. Total theoretical voting rights stood at 92,962,943, with 92,944,368 exercisable rights. This disclosure complies with French regulatory requirements.

SOHM, Inc. appointed Ravi Kapoor as an Independent Director. Kapoor brings over 30 years of experience in corporate law, M&A, and financial management. His expertise is expected to enhance SOHM’s strategic direction, corporate governance, and growth initiatives, particularly aligning with the company’s focus on generic drugs and gene-editing technologies.

Lipella Pharmaceuticals Inc. is delisted from the Nasdaq Capital Market due to rule violations regarding private placement transactions. The delisting, involving the issuance of convertible preferred stock and warrants, led to the suspension of trading. While disappointed, the company is exploring alternative markets, remains focused on its clinical development plans for LP-10 and LP-310, and is pressing forward with its mission to address unmet medical needs.

GRI Bio (NASDAQ: GRI), a San Diego-based biotech targeting iNKT cells for autoimmune therapies, will present its immunomodulatory platform at A.G.P.’s 2025 Healthcare Showcase on May 21 (2:40 PM ET) via live webcast. Dr. Marc Hertz, CEO, will outline advancements over traditional CAR-T approaches and highlight upcoming Phase II results for GRI-0621 (IPF/lupus pipelines) and its 500-compound library. The event attracts 500+ investors and historically correlates with 8% stock performance gains, offering critical visibility for the company’s early-inflammation intervention strategy. [99 words]

Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotech company developing Treg-targeted therapies for neuroinflammatory diseases, will headline H.C. Wainwright’s BioConnect Conference in New York City on May 16, 2025. CEO Dr. Arun Swaminathan will discuss the integration of its proprietary platforms, including lead compound COYA 302—a dual-pathway subcutaneous treatment combining LD IL-2 and CTLA4-Ig to address neuroinflammation. The company emphasizes its platforms’ potential in neurodegenerative, autoimmune, and metabolic disorders, while noting risks related to clinical timelines, regulation, and capital intensity in SEC filings. A live stream of the conference session will be available on its investor relations page for 90 days.